$CMPX News
Last published 2d ago
- 2d agoCMPXCompass Therapeutics, Inc. - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoCMPXCompass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswireCompass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA.Data from the COMPANION-002 study of tovecimig, including newly disclosed durability of
- 5d agoCMPXCompass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual MeetingGlobeNewswireCTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent
- 1w agoCMPXCompass Therapeutics to Participate in Upcoming November Investor EventsGlobeNewswireBOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 2w agoCMPXCompass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026GlobeNewswireAs published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or
- 4w agoCMPXCompass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 3mo agoCMPXCompass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswireThe Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA
- 3mo agoCMPXCompass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026GlobeNewswireBOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 4mo agoGTBPNKTXFATECMPX+1A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsPR NewswireDrug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital ...
- 5mo agoCMPXCRBUFATEGTBP+1After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellGlobeNewswireIssued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for
- 5mo agoCMPXCompass Therapeutics to Participate in Upcoming June Investor EventsGlobeNewswireBOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human
- 5mo agoCMPXCompass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual MeetingGlobeNewswireCTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies
- 6mo agoCMPXCompass Therapeutics to Participate in Upcoming May Investor EventsGlobeNewswireBOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human
- 6mo agoCMPXCompass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate UpdateGlobeNewswireAs recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versus paclitaxel alone
- 6mo agoCMPXTovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract CancerGlobeNewswireTovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median progression-free
- 6mo agoCMPXCompass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract CancerGlobeNewswireWebcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing
- 8mo agoCMPXCompass Therapeutics Reports 2025 Financial Results and Provides Corporate UpdateGlobeNewswireIn the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as
- 8mo agoCMPXMRKSGENPFE+8Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightPR NewswireThe biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing...
- 10mo agoBNTXCMPXIBRXONCYThe $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy EraGlobeNewswireVANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by
- 10mo agoCMPXCompass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 10mo agoCMPXCompass Therapeutics Announces Key Leadership AppointmentsGlobeNewswireBOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 10mo agoCMPXCompass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswireBOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that
- 11mo agoCMPXCompass Therapeutics to Participate in Upcoming December Investor EventsGlobeNewswireBOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that
- 1y agoCMPXCompass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireBased on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of
- 1y agoCMPXCompass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireCTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed select competitive
- 1y agoCMPXCompass Therapeutics to Participate in Upcoming November Investor EventsGlobeNewswireBOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat
- 1y agoCMPXCompass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoCMPXCompass Therapeutics to Participate in Upcoming September Investor EventsGlobeNewswireBOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat
- 1y agoCMPXCompass Therapeutics Announces Pricing of Upsized $120 Million Public OfferingGlobeNewswireBOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat
- 1y agoCMPXCompass Therapeutics Announces Proposed Public OfferingGlobeNewswireBOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat
- 1y agoCMPXCompass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswireIn the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that
- 1y agoCMPXCompass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025GlobeNewswireBOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its
- 1y agoCMPXCompass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that
- 1y agoCMPXCompass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate UpdateGlobeNewswireTovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including
- 1y agoCMPXCompass Therapeutics to Participate in Upcoming May Investor EventsGlobeNewswireBOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that
- 1y agoCMPXCompass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireCTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors.Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in
- 1y agoCMPXCompass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract CancerGlobeNewswireBOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first
- 1y agoCMPXCompass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology ForumGlobeNewswireBOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 1y agoCMPXTovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract CancerGlobeNewswireTovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with
- 1y agoCMPXCompass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract CancerGlobeNewswireWebcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing
- 1y agoCMPXCompass Therapeutics Reports 2024 Financial Results and Provides Corporate UpdateGlobeNewswireTop-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter
- 1y agoCMPXCompass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewswireBOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 1y agoCMPXCompass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug CandidateGlobeNewswireTop-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x VEGF-A bispecific) is
- 1y agoCMPXCompass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial OfficerGlobeNewswireBOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 1y agoCMPXCompass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswireBOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 1y agoCMPXCompass Therapeutics to Participate in Upcoming Investor EventsGlobeNewswireBOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 1y agoCMPXCompass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswireFully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first quarter of
- 2y agoCMPXCompass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireNew data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive biomarkers correlated
- 2y agoCMPXCompass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingGlobeNewswireBOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
- 2y agoCMPXCompass Therapeutics to Participate in Upcoming Investor EventsGlobeNewswireBOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple